BridgeBio Pharma Inc.

01/27/2022 | Press release | Distributed by Public on 01/27/2022 06:31

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)